AU2001261434A1 - Aldosterone antagonist composition for release during aldosterone acrophase - Google Patents

Aldosterone antagonist composition for release during aldosterone acrophase

Info

Publication number
AU2001261434A1
AU2001261434A1 AU2001261434A AU6143401A AU2001261434A1 AU 2001261434 A1 AU2001261434 A1 AU 2001261434A1 AU 2001261434 A AU2001261434 A AU 2001261434A AU 6143401 A AU6143401 A AU 6143401A AU 2001261434 A1 AU2001261434 A1 AU 2001261434A1
Authority
AU
Australia
Prior art keywords
aldosterone
acrophase
release during
antagonist composition
aldosterone antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261434A
Inventor
Susan M. Garthwaite
Leo K. Mathur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of AU2001261434A1 publication Critical patent/AU2001261434A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AU2001261434A 2000-05-11 2001-05-11 Aldosterone antagonist composition for release during aldosterone acrophase Abandoned AU2001261434A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20363700P 2000-05-11 2000-05-11
US60203637 2000-05-11
PCT/US2001/015236 WO2001087284A2 (en) 2000-05-11 2001-05-11 Aldosterone antagonist composition for release during aldosterone acrophase

Publications (1)

Publication Number Publication Date
AU2001261434A1 true AU2001261434A1 (en) 2001-11-26

Family

ID=22754728

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261434A Abandoned AU2001261434A1 (en) 2000-05-11 2001-05-11 Aldosterone antagonist composition for release during aldosterone acrophase

Country Status (6)

Country Link
US (2) US20020132001A1 (en)
EP (1) EP1280533A2 (en)
JP (1) JP2004501099A (en)
AU (1) AU2001261434A1 (en)
CA (1) CA2409437A1 (en)
WO (1) WO2001087284A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
DE60127410T2 (en) * 2000-07-27 2007-12-13 Pharmacia Corp. COMBINATION THERAPY WITH EPOXY-STEROIDAL ALDOSTERONE ANTAGONISTS AND CALCIUM CHANNEL BLOCKS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE
CA2469616A1 (en) 2001-12-12 2003-06-19 James W. Aiken Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
CA2474845A1 (en) * 2002-01-30 2003-08-07 Pharmacia Corporation Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
FR2841140B1 (en) * 2002-06-24 2004-10-01 Servier Lab MICROCAPSULES FOR DELAYED AND CONTROLLED RELEASE OF PERINDOPRIL
CA2495376A1 (en) * 2002-08-23 2004-03-04 Pharmacia Corporation Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s)
WO2004039361A1 (en) * 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
MXPA06006586A (en) * 2003-12-09 2007-02-21 Pharmasset Inc DOSING METHODS FOR ß-D-2aCO,3aCO-DIDEOXY-2aCO,3aCO-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY.
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
CN1938006B (en) * 2004-03-31 2010-11-10 Bpsi控股公司 Enteric coatings for orally ingestible substrates
PL1753398T3 (en) * 2004-06-10 2019-04-30 Glatt Air Techniques Inc Controlled release matrix pharmaceutical dosage formulation
WO2007012960A1 (en) * 2005-07-29 2007-02-01 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of eplerenone
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007097951A2 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
WO2008074098A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical composition
US20080152709A1 (en) * 2006-12-22 2008-06-26 Drugtech Corporation Clonidine composition and method of use
FR2917975B1 (en) * 2007-06-26 2009-10-16 Ceva Sante Animale Sa COMPOSITIONS AND TREATMENT OF CARDIAC INSUFFICIENCY IN NON-HUMAN MAMMAL ANIMALS
US20090270356A1 (en) * 2008-04-28 2009-10-29 Ceva Sante Animale Sa Compositions and treatments of heart failure in non-human mammal animals
US9345848B2 (en) 2009-10-20 2016-05-24 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Dry powder inhaler
WO2011146806A1 (en) * 2010-05-21 2011-11-24 University Of Florida Research Foundation, Inc. Methods for reducing anesthetic-inducible epileptogenic and neurotoxic effects
CN103153288B (en) * 2010-07-09 2017-02-15 詹姆斯·特林卡·格林 Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
TR201007653A2 (en) * 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Pharmaceutical composition containing eplerenone
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
JP6284884B2 (en) 2011-11-25 2018-02-28 ビルギチ，マフムト Inhaler
FR2991179B1 (en) * 2012-06-01 2016-11-11 Ceva Sante Animale ORAL VETERINARY COMPOSITIONS APPENDED
USD744087S1 (en) 2013-10-01 2015-11-24 Mahmut Bilgic Dry powder inhaler
US11007203B2 (en) * 2013-10-06 2021-05-18 Salim Shah Formulations comprising aldosterone receptor antagonists and treatments using same
US11737985B2 (en) * 2013-10-06 2023-08-29 Salim Shah Formulations comprising hydralazine, prazosin, torsemide, spironolactone, and/or naltrexone and treatments using same
CN109925293B (en) * 2019-03-15 2022-02-01 南京卡文迪许生物工程技术有限公司 Eplerenone oral solid preparation and preparation method thereof
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3013012A (en) * 1960-12-22 1961-12-12 Searle & Co Alkanoylthio-17alpha-carboxyethyl-17beta-hydroxyandrosten-3-one lactones
US4526777A (en) * 1983-01-06 1985-07-02 Mylan Pharmaceuticals Inc. Pharmaceutical combination composition and associated method
DE3305935C2 (en) * 1983-02-21 1985-05-30 Medice Chem.-Pharm. Fabrik Pütter GmbH & Co KG, 5860 Iserlohn Potassium neutral saluretic with antihypertensive effect
FI77669C (en) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-SPIROXANER OCH ANALOGER, SOM INNEHAOLLER EN OEPPEN RING E, FOERFARANDE FOER DERAS FRAMSTAELLNING SAMT DESSA INNEHAOLLANDE PHARMACEUTICAL PREPARATION.
GB9022788D0 (en) * 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
CZ297975B6 (en) * 1995-06-07 2007-05-09 G. D. Searle & Co. Pharmaceutical combination of angiotensin II receptor antagonist and receptor antagonist epoxymexrenone for treating cardiovascular disorders
MXPA01004381A (en) * 1998-11-02 2005-09-08 Elan Corp Plc Multiparticulate modified release composition.
UA74141C2 (en) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Oral pharmaceutical compositions comprising micronized eplerenone (variants), method for its production and method for treating aldosterone-mediated states (variants)
US6569456B2 (en) * 2000-01-13 2003-05-27 Osmotica Corp. Osmotic device containing diltiazem and an ACE inhibitor or diuretic

Also Published As

Publication number Publication date
EP1280533A2 (en) 2003-02-05
CA2409437A1 (en) 2001-11-22
US20020132001A1 (en) 2002-09-19
US20050192259A1 (en) 2005-09-01
JP2004501099A (en) 2004-01-15
WO2001087284A2 (en) 2001-11-22
WO2001087284A3 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
AU2001261434A1 (en) Aldosterone antagonist composition for release during aldosterone acrophase
AU2002300377A1 (en) Compositions for controlled release
HUP0301591A3 (en) Controlled release hydrocodone compositions
AU2001286233A1 (en) Cement composition
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
GB0218157D0 (en) Compositions for controlled release
AU2001278123A1 (en) Process for preparing polymer-based sustained release compositions
AU2276801A (en) Extended release oral dosage composition
AU2001245660A1 (en) Embolic compositions
AU9701101A (en) Methylphenidate modified release formulations
AU5250300A (en) Gas-generating agent composition for pretentioner
AU2002229140A1 (en) Controlled release pharmaceutical composition
AU2001250205A1 (en) Prostaglandin d2 receptor antagonists
AU2003219814A1 (en) Release agents
AU2001264264A1 (en) Sustained release compositions
AU2002338709A1 (en) Workability-improving agents for cement compositions
AU2001248772A1 (en) Sustained release drug compositions
AU2002215333A1 (en) Compositions for release of radiosensitizers, and methods of making and using the same
AU2002236588A1 (en) System for direct sequence spreading
AU2002221129A1 (en) Triglyceride depressant composition
AU2002226047A1 (en) Release agent composition
AU2001281349A1 (en) Bituminous substance removal composition
AU2001271018A1 (en) Gpr14 antagonist
AUPR040900A0 (en) Mould release composition
AU2003212866A1 (en) Controlled release compositions and methods for using same